Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Rybelsus (semaglutide) and Mounjaro (tirzepatide) are both medications used to treat type 2 diabetes, but they belong to different classes. Rybelsus is a glucagon-like peptide-1 (GLP-1) receptor agonist, while Mounjaro is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Rybelsus is taken orally once a day, whereas Mounjaro is injected under the skin once a week. Both medications are only available as a brand-name products. Both Rybelsus and Mounjaro can cause side effects like nausea, vomiting, and diarrhea, and have a warning about the risk of thyroid tumors or cancer. Mounjaro is the first medication in its class and can lower hemoglobin A1C levels more than Rybelsus. Both medications can interact with other diabetes medications, potentially causing low blood sugar, so it's important to monitor your blood sugar levels closely.
Rybelsus (semaglutide)
Mounjaro (tirzepatide)
Rybelsus (semaglutide)
Mounjaro (tirzepatide)
Summary of Rybelsus vs. Mounjaro
Summary for GLP-1 agonist
Prescription only
Rybelsus (semaglutide) is a brand-name GLP-1 agonist that helps lower blood sugar in adults with Type 2 diabetes. It's also FDA approved to help reduce the risk of heart attack, stroke, and heart-related death in people with Type 2 diabetes who are at risk for these events. The medication comes as a pill that's taken by mouth once a day, at least 30 minutes before you eat, drink, or take any other medications by mouth. It’s used along with diet and exercise, and might also help with weight loss. Common side effects include nausea, stomach pain, and diarrhea.